Positive new data on Boehringer and Click Thera’s CT-155

German family-owned pharma major Boehringer Ingelheim and Click Therapeutics today shared data from the pivotal Phase III CONVOKE study of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT) used as an adjunct to standard of care antipsychotic therapy for experiential negative symptoms of schizophrenia.

The data were presented during an oral session at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam and full results will be published at a later date.

Boehringer and Click first teamed in 2020, inking a deal with a total value of over $500 million to the US firm. They expanded the collaboration in 2022 to develop a second PDT for schizophrenia.